Multiple corporate presentations will be presented at ISHL.
Data from four analyses of the phase 3 ECHELON-1 clinical trial will be presented at ISHL. Importantly, an analysis from the ECHELON-1 study (Abstract #0038) will be presented in an oral presentation and poster showing PFS data per investigator that is consistent with the previously reported modified PFS data per Independent Review Facility.
Additional data presentations at ISHL include the following: Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma: Follow-up Results from the Phase 1/2 Study (Abstract #0005, oral presentation on Monday, October 29 at 14: 40-14: 50 CEST).
, we will present additional analyses from the ECHELON-1 trial, which demonstrated that ADCETRIS plus AVD improves upon a frontline standard of care regimen, ABVD, in advanced patients and resulted in the first change in advanced stage HL in over 40 years.
(10) MRI with gadolinium is also able to demonstrate presumed viral inflammation of the cochlear or vestibular membranous labyrinth in patients with ISHL
on T-1 weighted images.
(21.) Horatio Newhall to [J & J] Newhall, undated, Horatio Newhall Papers, folder 1, ISHL. See also Flower, History of the English Settlement, 157.
(28.) Horatio Newhall to [J & J] Newhall, May 21, 1823, Horatio Newhall Papers, folder 1, ISHL.
11,1823, Vaux Family Papers, HSP; Horatio Newhall to [J & J] Newhall, April 14, 1824, Horatio Newhall Papers, folder 1, ISHL.
The data to be presented at this years ISHL
are a proof point of the excellent progress we have made in furthering the clinical program of brentuximab vedotin, said Dirk Huebner, M.D., Executive Medical Director, Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company.